The original disclosure in Japanese was released on January 30, 2014 at 15:30 (GMT+9)

Consolidated Financial Statements for the Third Quarter Ended December 31, 2013
FY2014 (April 1, 2013 - March 31, 2014) [UNAUDITED]

Company name:	Takara Holdings Inc.
Stock exchange listings:	Tokyo Stock Exchange (1st section)
Code number:	2531
URL:	http://www.takara.co.jp/
Company representative:	Toshio Kakimoto, President
Contact:	Takuya Kakemi, General Manager of Financial & Investor Relations Dept.
	TEL: (075)241-5124

Quarterly statement filing date (as planned): February 7, 2014

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the nine months ended December 31, 2013 (April 1, 2013 – December 31, 2013)

(1) Operating results

Note: Percentages indicated changes from the previous fiscal year.

	Nine months ended December 31, 2013		Nine months ended December 31, 2012	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	159,519	2.9	155,025	0.7
Operating income	8,891	(2.9)	9,160	(5.8)
Ordinary income	9,205	(0.4)	9,245	(7.5)
Net income	10,503	117.6	4,826	14.2
Net income per share (Yen)	51.86		23.66	
Fully diluted net income per share (Yen)	51.85		23.66	
Note: Comprehensive income	23,207	324.5	5,466	111.2

(2) Financial position

	As of December 31, 2013	As of March 31, 2013
	(Millions of yen)	(Millions of yen)
Total assets	242,316	207,586
Net assets	142,764	114,318
Equity ratio (%)	49.1	48.2
(Reference) Equity	118,879	100,040

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2013	Year ending March 31, 2014	Year ending March 31, 2014 (Forecast)
First quarter end	-	-	
Second quarter end	-	-	
Third quarter end	-	-	
Year end	9.00		9.00
Annual	9.00		9.00

Note: Correction of dividend forecast from the most recent dividend forecast : No

3. Forecast for the year ending March 31, 2014 (April 1, 2013 – March 31, 2014)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2014	
	(Millions of yen)	(%)
Net sales	209,000	4.0
Operating income	9,300	1.8
Ordinary income	9,600	3.3
Net income	9,700	106.9
Net income per share (Yen)	47.96	

Note: Correction of financial forecast from the most recent financial forecast : No

4. Others

(1) Material changes in subsidiaries during this period
(Changes in scope of consolidations resulting from change is subsidiaries) : No

(2) Applying of specific accounting of the consolidated quarterly financial statements : No

(3) Changes in accounting policies, accounting estimates and retrospective restatement

1) Changes based on revisions of accounting standard : No

2) Changes other than ones based on revisions of accounting standard : No

3) Changes in accounting estimates : No

4) Restatement : No

(4) Number of outstanding shares (common stock)

1) Number of outstanding shares at year end (Treasury stocks are included)

As of December 31, 2013 :	217,699,743
As of March 31, 2013 :	217,699,743

2) Number of treasury stocks at year end

As of December 31, 2013 :	16,364,003
As of March 31, 2013 :	14,833,716

3) Average number of outstanding shares

Nine months ended December 31, 2013 :	202,553,399
Nine months ended December 31, 2012 :	204,014,617

Contents of the attached document

1. Qualitative Information for the Nine Months Ended December 31, 2013 ---------- 2
   (1) Consolidated Financial Results ---------- 2
   (2) Consolidated Financial Position ---------- 3
   (3) Qualitative Information Regarding Consolidated Forecasts ---------- 4
2. Consolidated Quarterly Financial Statements ---------- 5
   (1) Consolidated Quarterly Balance Sheets ---------- 5
   (2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income ---------- 7
   Consolidated Quarterly Statements of Income
   (For the Nine Months Ended December 31, 2013 and 2012) ---------- 7
   Consolidated Quarterly Statements of Comprehensive Income
   (For the Nine Months Ended December 31, 2013 and 2012) ---------- 8
   (3) Notes on Consolidated Quarterly Financial Statements ---------- 9
   (Notes on Premise of Going Concern) ---------- 9
   (Notes on Material Changes in Shareholders' Equity) ---------- 9
   (Segment Information) ---------- 9

○ Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Nine Months Ended December 31, 2013

(1) Consolidated Financial Results

In the nine months ended December 31, 2013, the Japanese economy saw recovery in consumer confidence stemming from the influences of yen depreciation and rising stock prices. In addition, performance of companies improved, particularly for exporters, and there was recovery in capital investment. These factors created a gentle recovery trend in the domestic economy. Nevertheless, there was cause for concern including economic slowdown in emerging countries, higher prices for general consumer goods resulted from the rise in prices for imported raw materials that accompanied yen depreciation, and projected demand trends before and after the scheduled consumption tax hike in Japan. Accordingly, the future of operating environment remains unclear.

In this environment, we endeavored to improve corporate value through the establishment of a balanced organizational structure that is resilient to changes in the environment by acting in accordance with the Takara Group Medium-Term Management Plan FY2014, which has "aiming to realize the Takara Group Vision2020, achieve stable growth in Japan while expanding business base in order to grow significantly overseas" as its basic policy. The Takara Group Vision 2020 embodies our long-term management vision.

In the domestic alcoholic beverages business, the Group focused its resources on developing original new products and cultivating brands in response to diversifying customer preferences. In the seasonings and raw alcohol business, the Group made concerted efforts to increase sales by proposing differentiated products that meet customer needs.

In the overseas alcoholic beverages business and the Japanese food ingredients wholesale business, the Group worked to accelerate business expansion by spreading Japanese food culture across the globe. In addition, management rights in Tazaki Foods Limited, which conducts a Japanese food ingredient wholesale business in the United Kingdom, were acquired in September 2013.

In the Biomedical business, management resources were focused on three areas—the genetic engineering research business, the gene medicine business, and the agribio business—in pursuit of improved performance.

In the nine months ended December 31, 2013, net sales rose by a slight 2.9% year on year, to ¥159,519 million, as a result of the influences of yen depreciation among other factors. The rise in sales boosted gross profit, but a higher cost of sales ratio limited this increase, and gross profit only rose 1.8%, to ¥61,491 million.

Selling, general and administrative (SG&A) expenses were up 2.6% year on year, to ¥52,599 million, following rises in personnel expenses, including those resulted from yen depreciation, and other factors. Consequently, operating income decreased 2.9%, to ¥8,891 million. In regard to non-operating income and expenses, stock issuance cost was recorded in relation to the public tender offer by Takara Bio Inc. However, this was offset by a rise in equity in earnings of affiliates as well as by the fact that the foreign exchange losses recorded in the nine months ended December 31, 2012, were replaced with foreign exchange gains and the bond issuance cost recorded in the previous corresponding period was not recorded in the period under review. These factors resulted in a slight improvement in the balance of non-operating items, and ordinary income decreased only 0.4%, to ¥9,205 million, accordingly.

In regard to extraordinary income and loss, extraordinary income was recorded from the sale of a portion of the stock held by the Company in Takara Bio, which was conducted in conjunction with this company's public stock offer. Combined with a decline in loss on sales and retirement of noncurrent assets, this resulted in a significant improvement in the balance of these items. As a result, income before income taxes and minority interests showed a substantial increase of 113.6% year on year, to ¥18,397 million, and net income jumped 117.6%, to ¥10,503 million.

Results by business segment were as follows.

[Takara Shuzo Group]

In the nine months ended December 31, 2013, net sales for the Takara Shuzo Group edged up 1.8% year on year, to ¥140,850 million. This increase can be attributed to the sales contributions from the newly consolidated Tazaki Foods Limited as well as the benefits from yen depreciation when translating sales of overseas subsidiaries to yen.

By product category, overall sales of shochu products decreased substantially following sluggish sales of all products, including honkaku shochu, and significantly lower sales for standard ko-type shochu. Conversely, sparkling sake Sho-Chiku-Bai Shirakabe-gura Mio, which we expanded sales channels for in September 2013, experienced strong sales growth, leading to an overall rise in sake sales. In light-alcohol refreshers, Takara Shochu High Ball maintained its popularity and contributions from new products led to sales increases. Similarly, impressive sales of wine and whiskey contributed to higher sales of other liquors. However, the decline in shochu sales weighed heavily, and overall sales of alcoholic beverages decreased as a result.

Meanwhile, the Japanese food ingredients wholesale business, included in the other category, experienced significant sales increases in foreign currency, which were further amplified by the influences of yen depreciation. Coupled with the abovementioned sales contributions from Tazaki Foods Limited, this resulted in the other category posting a substantial year-on-year increase in sales, which helped the entire segment record higher sales.

Cost of sales was up 2.8% year on year, to ¥89,404 million, due to rising raw material prices and a higher cost of sales ratio following changes in product mixes. For this reason, gross profit only rose by a slight 0.1%, to ¥51,446 million. SG&A expenses increased 1.4%, to ¥44,404 million, due to higher transportation costs and personnel expenses among other factors, and operating income for the Takara Shuzo Group declined 7.1%, to ¥7,041 million, accordingly.

[Takara Bio Group]
In the nine months ended December 31, 2013, net sales for the Takara Bio Group increased 16.2% year on year, to ¥16,167 million, as a result of increases in sales of research reagents in the genetic engineering research business and the strong performance of the gene medicine business.

In the genetic engineering research business, sales of mainstay research reagents were up. This was due in part to the influences of yen depreciation. In addition, sales of scientific instruments rose following higher sales of mass spectrometry equipment and other instruments, and sales of contract research services grew. In the gene medicine business, favorable sales of cell culture media and gas-permeable bags led to an overall increase in sales. As for the agribio business, a decline in sales of mushroom-related products offset a rise in health food sales, resulting in an overall decrease in sales.

Cost of sales was up 19.5%, to ¥7,500 million, due to differences between the cost of sales ratios of individual products. Regardless, gross profit increased 13.4%, to ¥8,666 million. Higher personnel expenses, R&D expenses, and other factors led to an 11.9% increase in SG&A expenses, to ¥7,758 million, but operating income rose 28.3%, to ¥908 million, regardless.

[Takara Healthcare]
In the nine months ended December 31, 2013, net sales for Takara Healthcare took a substantial drop of 36.3% year on year, to ¥1,027 million, due to the end of the tea beverages PB supply business. In health care business, net sales rose 10.2% when the tea beverages PB supply business is excluded from consideration. This was because sales were up for mainstay fucoidan-related products and sales of other products were favorable. Gross profit declined in conjunction with the end of the tea beverages PB supply business. Nevertheless, we worked to reduce SG&A expenses and were thereby successful in recording operating income of ¥5 million, compared with operating loss of ¥22 million in the previous equivalent period.

[Other]
Net sales of business segments other than the reported segments decreased 2.0% year on year, to ¥5,541 million, but operating income was up 48.0%, to ¥201 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2012, to December 31, 2012)	Period under Review (from April 1, 2013, to December 31, 2013)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo Group			
Shochu	55,840	51,992	93.1
Sake	17,781	18,769	105.6
Light-alcohol refreshers	19,905	21,228	106.6
Other liquors	8,458	9,297	109.9
Alcoholic beverages total	101,985	101,288	99.3
Hon Mirin	11,834	11,655	98.5
Other seasonings	6,208	6,658	107.3
Seasonings total	18,043	18,314	101.5
Raw alcohol, etc.	5,141	5,065	98.5
Transportation	8,549	8,937	104.5
Other	4,648	7,245	155.9
Total	138,367	140,850	101.8
Takara Bio Group	13,916	16,167	116.2
Takara Healthcare	1,612	1,027	63.7
Other	5,654	5,541	98.0
Sales not allocated to business segments and intersegment transactions	(4,525)	(4,067)	-
Total	**155,025**	**159,519**	**102.9**

Note: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position
Total assets stood at ¥242,316 million as of December 31, 2013, up ¥34,729 million from March 31, 2013, the end of the previous fiscal year. Current assets increased ¥20,109 million, to ¥153,394 million, due to factors including a rise in notes and accounts receivable-trade of ¥13,706 million, which can be attributed to the influences of the lucrative

year-end season, as well as increases of ¥2,979 million in cash and deposits and ¥3,381 million in inventories. Noncurrent assets increased ¥14,620 million, to ¥88,921 million, following a ¥2,694 million increase in property, plant and equipment as well as an increase of ¥2,698 million in goodwill associated with the acquisition of new subsidiaries and a rise of ¥8,959 million in investment securities, which is the result of increases in mark-to-market valuation of listed securities and measures to temporarily manage surplus revenues.

Total liabilities amounted to ¥99,551 million as of December 31, 2013, up ¥6,283 million from March 31, 2013. This was because the decrease resulted from the redemption of ¥5,000 million of current portion of bonds was offset by an increase of ¥3,109 million in liquor taxes payable as well as an increase of ¥3,797 million in income taxes payable, which was a result of the recording of gain on sales of subsidiaries and affiliates' stocks.

Total net assets were ¥142,764 million as of December 31, 2013, up ¥28,446 million from March 31, 2013, due to an increase of ¥9,608 million in minority interests as well as an increase of ¥14,525 million in retained earnings, which was the result of the change in equity in Takara Bio following its issuance of new shares through a public stock offer and strong growth in net income.

(3) Qualitative Information Regarding Consolidated Forecasts

A revision to the initial full-year forecasts for consolidated performance in the year ending March 31, 2014, was instituted on November 1, 2013. As of December 31, 2013, consolidated performance was generally in line with these revised forecasts. Accordingly, the Company has chosen not to revise the consolidated forecasts released on November 1, 2013.

2. Consolidated Quarterly Financial Statements

(1) Consolidated Quarterly Balance Sheets

(Millions of yen)

	As of Mar. 31, 2013	As of Dec. 31, 2013
Assets		
Current assets		
Cash and deposits	36,789	39,768
Notes and accounts receivable-trade	50,630	64,336
Securities	15,260	14,979
Merchandise and finished goods	21,773	24,388
Work in process	1,090	1,170
Raw materials and supplies	2,841	3,528
Other	4,982	5,353
Allowance for doubtful accounts	(82)	(129)
Total current assets	133,285	153,394
Noncurrent assets		
Property, plant and equipment	42,639	45,334
Intangible assets		
Goodwill	3,767	6,465
Other	1,659	1,792
Total intangible assets	5,426	8,258
Investments and other assets		
Investment securities	21,080	30,039
Other	5,364	5,509
Allowance for doubtful accounts	(209)	(220)
Total investments and other assets	26,235	35,329
Total noncurrent assets	74,301	88,921
Total assets	207,586	242,316
Liabilities		
Current liabilities		
Notes and accounts payable-trade	13,028	14,516
Short-term loans payable	5,006	5,843
Current portion of bonds	5,000	―
Accrued alcohol tax	9,907	13,017
Accrued expenses	4,698	5,264
Income taxes payable	1,996	5,793
Provision for sales promotion expenses	1,719	2,045
Other provision	2,014	1,254
Other	6,023	6,741
Total current liabilities	49,394	54,476
Noncurrent liabilities		
Bonds payable	25,000	25,000
Long-term loans payable	417	318
Provision for retirement benefits	8,845	8,658
Long-term deposits received	5,626	5,609
Other	3,983	5,488
Total noncurrent liabilities	43,873	45,074
Total liabilities	93,268	99,551

(Millions of yen)

	As of Mar. 31, 2013	As of Dec. 31, 2013
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	3,195	3,195
Retained earnings	90,437	104,963
Treasury stock	(8,355)	(9,856)
Total shareholders' equity	98,503	111,528
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	4,599	7,089
Deferred gains or losses on hedges	16	401
Foreign currency translation adjustment	(3,079)	(140)
Total accumulated other comprehensive income	1,537	7,350
Minority interests	14,277	23,885
Total net assets	114,318	142,764
Total liabilities and net assets	207,586	242,316

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Stetements of Comprehensive Income

(Consolidated Quarterly Statements of Income)

(For the Nine Months Ended December 31, 2013 and 2012)

(Millions of Yen)

	FY2013_3Q (Apr. 1, 2012 - Dec. 31, 2012)	FY2014_3Q (Apr. 1, 2013 - Dec. 31, 2013)
Net sales	155,025	159,519
Cost of sales	94,618	98,027
Gross profit	60,407	61,491
Selling, general and administrative expenses	51,246	52,599
Operating income	9,160	8,891
Non-operating income		
Dividends income	348	357
Other	369	445
Total non-operating income	717	802
Non-operating expenses		
Interest expenses	400	340
Other	233	147
Total non-operating expenses	633	488
Ordinary income	9,245	9,205
Extraordinary income		
Gain on sales of subsidiaries and affiliates' stocks	—	9,261
Gain on revision of retirement benefit plan	345	—
Other	321	192
Total extraordinary income	666	9,453
Extraordinary loss		
Loss on sales and retirement of noncurrent assets	528	103
Loss on transfer of land	—	121
Contribution for withdrawal from employees pension fund	260	—
Other	508	36
Total extraordinary losses	1,297	262
Income before income taxes and minority interests	8,614	18,397
Income taxes-current	3,287	7,151
Income taxes-deferred	189	422
Total income taxes	3,477	7,574
Income before minority interests	5,137	10,823
Minority interests in income	311	319
Net income	4,826	10,503

(Consolidated Quarterly Statements of Comprehensive Income)

(For the Nine Months Ended December 31, 2013 and 2012)

(Millions of Yen)

	FY2013_3Q (Apr. 1, 2012 - Dec. 31, 2012)	FY2014_3Q (Apr. 1, 2013 - Dec. 31, 2013)
Income before minority interests	5,137	10,823
Other comprehensive income		
Valuation difference on available-for-sale securities	143	2,489
Deferred gains or losses on hedges	33	387
Foreign currency translation adjustment	152	3,429
Share of other comprehensive income of associates accounted for using equity method	(0)	230
Gain or loss on change in equity	—	5,847
Total other comprehensive income	329	12,384
Comprehensive income	5,466	23,207
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	5,119	22,164
Comprehensive income attributable to minority interests	347	1,042

(4) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2012, to December 31, 2012)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	137,774	13,502	1,609	152,886	1,811	154,697	327	155,025
Intersegment	592	413	2	1,009	3,843	4,852	(4,852)	-
Total	138,367	13,916	1,612	153,895	5,654	159,550	(4,525)	155,025
Segment income (loss)	7,582	707	(22)	8,267	136	8,403	757	9,160

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income (loss) comprises intersegment eliminations of ¥89 million and income of the Company not allocated to business segments of ¥667 million.
3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No significant items requiring inclusion.

II. Period under Review (From April 1, 2013, to December 31, 2013)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	140,593	15,711	1,025	157,330	1,866	159,196	322	159,519
Intersegment	257	455	1	714	3,674	4,389	(4,389)	-
Total	140,850	16,167	1,027	158,045	5,541	163,586	(4,067)	159,519
Segment income (loss)	7,041	908	5	7,955	201	8,156	734	8,891

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income (loss) comprises intersegment eliminations of ¥58 million and income of the Company not allocated to business segments of ¥675 million.
3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No significant items requiring inclusion.

平成26年3月期
第3四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Third Quarter Ended December 31, 2013

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書
Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造グループ
Takara Shuzo Group

要約損益計算書
Statements of Income (Summary)

3. タカラバイオグループ
Takara Bio Group

要約損益計算書
Statements of Income (Summary)

4. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

財務・IR部 Financial & Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5127
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　財務・IR部
Takara Holdings Inc. Financial & Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5127
E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 Consolidated Statements of Income by Business Group (Summary)　→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成25年3月期 第3四半期累計	平成26年3月期 第3四半期累計 Apr. 1, 2013 - Dec. 31, 2013			平成25年3月期 通期	平成26年3月期 通期 Apr. 1, 2013 - Mar. 31, 2014		
	実績(a) FY2013(1Q-3Q) Actual (a)	実績(b) FY2014(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2013 Actual (c)	11/1予想(d) FY2014 Forecast announced Nov. 2013 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
宝酒造 グループ Takara Shuzo Group	138,367	140,850	2,483	101.8%	176,946	182,100	5,153	102.9%
タカラバイオ グループ Takara Bio Group	13,916	16,167	2,251	116.2%	20,564	23,700	3,135	115.2%
宝ヘルスケア Takara Healthcare Inc.	1,612	1,027	△ 585	63.7%	2,008	1,350	△ 658	67.2%
その他 Other, net	1,129	1,473	344	130.5%	1,469	1,850	380	125.9%
売上高 Net sales	155,025	159,519	4,493	102.9%	200,989	209,000	8,010	104.0%
売上原価 Cost of sales	94,618	98,027	3,409	103.6%	123,630	128,500	4,869	103.9%
売上総利益 Gross profit	60,407	61,491	1,083	101.8%	77,359	80,500	3,140	104.1%
運送費、保管料 Transportation and storage	5,679	5,895	216	103.8%	7,324	7,700	375	105.1%
広告宣伝費 Advertising	3,243	3,079	△ 163	94.9%	3,797	3,500	△ 297	92.2%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	24,283	24,214	△ 69	99.7%	32,838	33,400	561	101.7%
研究開発費 Research and development	2,264	2,412	147	106.5%	3,090	3,700	609	119.7%
管理費、その他 Other, net	15,774	16,997	1,223	107.8%	21,174	22,900	1,725	108.1%
販売費及び一般管理費 SG&A expenses	51,246	52,599	1,353	102.6%	68,225	71,200	2,974	104.4%
宝酒造 グループ Takara Shuzo Group	7,582	7,041	△ 540	92.9%	6,387	6,200	△ 187	97.1%
タカラバイオ グループ Takara Bio Group	707	908	200	128.3%	1,691	1,900	208	112.3%
宝ヘルスケア Takara Healthcare Inc.	△ 22	5	28	—	△ 22	8	30	—
その他 Other, net	893	936	42	104.8%	1,076	1,192	115	110.7%
営業利益(△:損失) Operating income(Δ:loss)	9,160	8,891	△ 269	97.1%	9,133	9,300	166	101.8%
受取利息・配当金 Interest and Dividends income	464	469	4	101.0%	536	500	△ 36	93.3%
その他営業外収益 Other, net	252	332	80	131.7%	488	500	11	102.3%
営業外収益 Non-operating income	717	802	84	111.8%	1,025	1,000	△ 25	97.6%
支払利息 Interest and discounts expenses	400	340	△ 59	85.2%	523	500	△ 23	95.5%
その他営業外費用 Other, net	233	147	△ 85	63.2%	338	200	△ 138	59.1%
営業外費用 Non-operating expenses	633	488	△ 144	77.1%	862	700	△ 162	81.2%
経常利益(△:損失) Ordinary income(Δ:loss)	9,245	9,205	△ 39	99.6%	9,296	9,600	303	103.3%
特別利益 Extraordinary gain	666	9,453	8,786	1417.5%	1,948	9,400	7,451	482.4%
特別損失 Extraordinary loss	1,297	262	△ 1,035	20.2%	1,989	1,200	△ 789	60.3%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	8,614	18,397	9,782	213.6%	9,256	17,800	8,543	192.3%
法人税、住民税及び事業税 Current income taxes	3,287	7,151	3,863	217.5%	3,390	7,600	3,591	189.6%
法人税等調整額 Deferred income taxes	189	422	233	223.1%	618			
少数株主損益調整前四半期純利益(△:損失) Income(Δ:loss) before minority interests	5,137	10,823	5,685	210.7%	5,247	10,200	4,952	194.4%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	311	319	7	102.5%	560	500	△ 60	89.2%
四半期純利益(△:損失) Net income(Δ:loss)	4,826	10,503	5,677	217.6%	4,687	9,700	5,012	206.9%
設備投資額(有形・無形) Capital expenditures	4,102	5,324	1,221	129.8%	5,282	9,188	3,906	173.9%
減価償却費(有形・無形) Depreciation and Amortization	3,132	3,111	△ 21	99.3%	4,251	4,000	△ 251	94.1%

営業外収益 Non-operating income	受取利息112、受取配当金357、持分法による投資利益112 など Interest income 112, Dividends income 357, Equity in earnings of affiliates 112, etc.
営業外費用 Non-operating expenses	支払利息120、社債利息220、株式交付費63 など Interest expense 120, Interest on bonds 220, Stock issuance cost 63, etc.
特別利益 Extraordinary gain	関係会社株式売却益9,261 など Gain on sales of subsidiaries and affiliates' stocks 9,261, etc.
特別損失 Extraordinary loss	固定資産除売却損103 など (前期:固定資産除売却損528、投資有価証券評価損375、厚生年金基金脱退拠出金260 など) Loss on sales and retirement of noncurrent assets 103, etc. (FY2013(1Q-3Q): Loss on sales and retirement of noncurrent assets 528, Loss on valuation of investment securities 375, Contribution for withdrawal from employees pension fund 260, etc.)

2. 宝酒造グループ Takara Shuzo Group

要約損益計算書 Statements of Income (Summary)

→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成25年3月期 第3四半期累計	平成26年3月期 第3四半期累計 Apr. 1, 2013 - Dec. 31, 2013			平成25年3月期 通期	平成26年3月期 通期 Apr. 1, 2013 - Mar. 31, 2014		
	実績(a) FY2013(1Q-3Q) Actual (a)	実績(b) FY2014(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2013 Actual (c)	11/1予想(d) FY2014 Forecast announced Nov. 2013 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
焼酎 Shochu	55,840	51,992	△ 3,847	93.1%	70,630	66,700	△ 3,930	94.4%
清酒 Sake	17,781	18,769	988	105.6%	21,737	24,000	2,262	110.4%
ソフトアルコール飲料 Light-alcohol refreshers	19,905	21,228	1,322	106.6%	25,757	27,600	1,842	107.2%
その他酒類 Other liquors	8,458	9,297	839	109.9%	11,047	11,900	852	107.7%
本みりん Hon Mirin	11,834	11,655	△ 179	98.5%	14,553	14,500	△ 53	99.6%
その他調味料 Other seasonings	6,208	6,658	450	107.3%	7,830	8,500	669	108.5%
原料用アルコール等 Raw alcohol	5,141	5,065	△ 75	98.5%	6,922	6,800	△ 122	98.2%
その他 Other	13,197	16,182	2,984	122.6%	18,468	22,100	3,631	119.7%
売上高 Net sales	138,367	140,850	2,483	101.8%	176,946	182,100	5,153	102.9%
売上原価 Cost of sales	86,994	89,404	2,410	102.8%	112,384	115,900	3,515	103.1%
売上総利益 Gross profit	51,372	51,446	73	100.1%	64,562	66,200	1,637	102.5%
運送費、保管料 Transportation and storage	5,177	5,424	247	104.8%	6,668	7,100	431	106.5%
広告宣伝費 Advertising	2,966	2,757	△ 208	93.0%	3,420	3,100	△ 320	90.6%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	23,542	23,422	△ 120	99.5%	31,815	32,400	584	101.8%
研究開発費 Research and development	272	250	△ 21	92.0%	363	400	36	110.0%
管理費、その他 Other, net	11,831	12,549	718	106.1%	15,906	17,000	1,093	106.9%
販売費及び一般管理費 SG&A expenses	43,789	44,404	614	101.4%	58,174	60,000	1,825	103.1%
営業利益(△:損失) Operating income(Δ:loss)	7,582	7,041	△ 540	92.9%	6,387	6,200	△ 187	97.1%
営業外収益 Non-operating income	298	350	52	117.4%	472	400	△ 72	84.7%
営業外費用 Non-operating expenses	206	179	△ 27	86.8%	328	200	△ 128	60.8%
経常利益(△:損失) Ordinary income(Δ:loss)	7,675	7,213	△ 461	94.0%	6,531	6,400	△ 131	98.0%
特別利益 Extraordinary gain	149	118	△ 31	79.1%	172	10	△ 162	5.8%
特別損失 Extraordinary loss	549	225	△ 324	41.0%	596	460	△ 136	77.2%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	7,275	7,106	△ 168	97.7%	6,107	5,950	△ 157	97.4%
法人税、住民税及び事業税 Current income taxes	2,834	2,741	△ 92	96.7%	2,510	2,700	112	104.4%
法人税等調整額 Deferred income taxes	177	156	△ 21	87.8%	77			
少数株主損益調整前四半期純利益(△:損失) Income(Δ:loss) before minority interests	4,263	4,209	△ 54	98.7%	3,520	3,250	△ 270	92.3%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	101	136	35	134.5%	139	150	10	107.7%
四半期純利益(△:損失) Net income(Δ:loss)	4,161	4,072	△ 89	97.8%	3,381	3,100	△ 281	91.7%
設備投資額(有形・無形) Capital expenditures	1,735	1,969	234	113.5%	2,529	2,293	△ 235	90.7%
減価償却費(有形・無形) Depreciation and Amortization	2,205	2,143	△ 62	97.2%	2,997	2,900	△ 97	96.8%

*平成25年3月期の実績において、「ソフトアルコール飲料」の一部を「焼酎」に、「その他」の一部を「その他酒類」にそれぞれ組替えております。
(平成26年3月期の区分に合わせております。)

3. タカラバイオグループ Takara Bio Group

要約損益計算書 Statements of Income (Summary)

→[参考:通期 Reference:Full year]

(百万円 Millions of Yen)

	平成25年3月期 第3四半期累計	平成26年3月期 第3四半期累計 Apr. 1, 2013 - Dec. 31, 2013			平成25年3月期 通期	平成26年3月期 通期 Apr. 1, 2013 - Mar. 31, 2014		
	実績(a) FY2013(1Q-3Q) Actual (a)	実績(b) FY2014(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)	実績(c) FY2013 Actual (c)	1/30予想(d) FY2014 Forecast announced Jan. 2014 (d)	増減(d-c) Change (d-c)	比(d/c) YOY% (d/c)
研究用試薬 Research reagents	8,455	10,273	1,818	121.5%	12,096	14,626	2,529	120.9%
理化学機器 Scientific instruments	1,506	1,634	128	108.5%	2,535	2,637	102	104.1%
受託・その他ファイン Contracted service and other	1,353	1,566	213	115.8%	2,365	2,615	249	110.6%
遺伝子工学研究 計 Genetic engineering research segment	11,315	13,475	2,159	119.1%	16,997	19,879	2,882	117.0%
遺伝子医療 Gene medicine segment	886	1,045	159	118.0%	1,240	1,535	294	123.8%
医食品バイオ Agribio segment	1,713	1,645	△ 67	96.0%	2,326	2,285	△ 41	98.2%
売上高 Net sales	13,916	16,167	2,251	116.2%	20,564	23,700	3,135	115.2%
売上原価 Cost of sales	6,275	7,500	1,224	119.5%	9,540	11,134	1,594	116.7%
売上総利益 Gross profit	7,640	8,666	1,026	113.4%	11,024	12,565	1,541	114.0%
運送費、保管料 Transportation and storage	355	393	37	110.6%	476	536	59	112.5%
広告宣伝費 Advertising	58	94	35	160.5%	89	122	32	136.3%
販売促進費 Sales promotion	696	732	36	105.2%	963	939	△ 23	97.5%
研究開発費 Research and development	1,993	2,154	160	108.1%	2,715	3,100	384	114.1%
管理費、その他 Other, net	3,828	4,383	555	114.5%	5,086	5,966	880	117.3%
販売費及び一般管理費 SG&A expenses	6,932	7,758	825	111.9%	9,332	10,665	1,332	114.3%
遺伝子工学研究 Genetic engineering research segment	2,989	3,198	209	107.0%	4,831	5,071	239	105.0%
遺伝子医療 Gene medicine segment	△ 817	△ 898	△ 80	—	△ 1,112	△ 1,254	△ 141	—
医食品バイオ Agribio segment	△ 175	△ 165	9	—	△ 304	△ 257	47	—
共通 Eliminations/Corporate	△ 1,288	△ 1,227	61	—	△ 1,722	△ 1,658	63	—
営業利益(△:損失) Operating income(Δ:loss)	707	908	200	128.3%	1,691	1,900	208	112.3%
営業外収益 Non-operating income	130	164	34	126.2%	322	338	15	104.8%
営業外費用 Non-operating expenses	39	81	41	204.9%	49	88	39	179.4%
経常利益(△:損失) Ordinary income(Δ:loss)	798	991	193	124.2%	1,965	2,150	185	109.4%
特別利益 Extraordinary gain	346	0	△ 346	0.1%	348	0	△ 348	0.1%
特別損失 Extraordinary loss	28	34	5	119.2%	44	56	11	124.5%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	1,116	957	△ 158	85.8%	2,268	2,094	△ 174	92.3%
法人税、住民税及び事業税 Current income taxes	412	545	132	132.2%	587	742	△ 66	91.8%
法人税等調整額 Deferred income taxes	△ 8	△ 125	△ 117	—	222			
少数株主損益調整前四半期純利益(△:損失) Income(Δ:loss) before minority interests	711	537	△ 174	75.5%	1,459	1,352	△ 107	92.6%
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	△ 1	△ 5	△ 3	—	△ 3	2	5	—
四半期純利益(△:損失) Net income(Δ:loss)	713	542	△ 171	76.0%	1,462	1,350	△ 112	92.3%
設備投資額(有形・無形) Capital expenditures	2,058	3,230	1,171	156.9%	2,397	6,237	3,839	260.1%
減価償却費(有形・無形) Depreciation and Amortization	817	849	32	104.0%	1,104	1,150	46	104.2%

4. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		平成21年3月期 第3四半期累計 FY2009(1Q-3Q)	平成22年3月期 第3四半期累計 FY2010(1Q-3Q)	平成23年3月期 第3四半期累計 FY2011(1Q-3Q)	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	前期対比 Change from FY2013(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	149,565	147,932	147,969	153,915	155,025	159,519	4,493	102.9%
売上原価	Cost of sales	91,788	89,345	89,423	93,282	94,618	98,027	3,409	103.6%
（売上高原価率）	(Ratio to Net sales)	61.4%	60.4%	60.4%	60.6%	61.0%	61.5%	+0.4pt	—
売上総利益	Gross profit	57,776	58,587	58,545	60,633	60,407	61,491	1,083	101.8%
販売費及び一般管理費	SG&A expenses	48,741	49,333	49,271	50,907	51,246	52,599	1,353	102.6%
（売上高販管費率）	(Ratio to Net sales)	32.6%	33.3%	33.3%	33.1%	33.1%	33.0%	-0.1pt	—
営業利益（△：損失）	Operating income(Δ:loss)	9,034	9,253	9,274	9,725	9,160	8,891	△ 269	97.1%
（売上高営業利益率）	(Ratio to Net Sales)	6.0%	6.3%	6.3%	6.3%	5.9%	5.6%	-0.3pt	—
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	21,860	22,544	22,768	23,723	24,283	24,214	△ 69	99.7%
（売上高販促費率）	(Ratio to Net sales)	14.6%	15.2%	15.4%	15.4%	15.7%	15.2%	-0.5pt	—
研究開発費	R&D expenses	2,440	2,525	2,103	2,169	2,264	2,412	147	106.5%
（売上高研究開発費率）	(Ratio to Net sales)	1.6%	1.7%	1.4%	1.4%	1.5%	1.5%	+0.1pt	—
設備投資額（有形・無形）	Capital expenditures	2,306	2,617	2,422	3,694	4,102	5,324	1,221	129.8%
減価償却費（有形・無形）	Depreciation and Amortization	3,762	3,589	3,352	3,284	3,132	3,111	△ 21	99.3%

宝酒造グループ :Takara Shuzo Group

（百万円 :Millions of Yen）

		平成21年3月期 第3四半期累計 FY2009(1Q-3Q)	平成22年3月期 第3四半期累計 FY2010(1Q-3Q)	平成23年3月期 第3四半期累計 FY2011(1Q-3Q)	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	前期対比 Change from FY2013(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	132,594	130,996	131,604	137,671	138,367	140,850	2,483	101.8%
売上原価	Cost of sales	83,393	80,973	81,436	85,802	86,994	89,404	2,410	102.8%
（売上高原価率）	(Ratio to Net sales)	62.9%	61.8%	61.9%	62.3%	62.9%	63.5%	+0.6pt	—
売上総利益	Gross profit	49,201	50,023	50,168	51,868	51,372	51,446	73	100.1%
販売費及び一般管理費	SG&A expenses	41,018	41,871	42,038	43,813	43,789	44,404	614	101.4%
（売上高販管費率）	(Ratio to Net sales)	30.9%	32.0%	31.9%	31.8%	31.6%	31.5%	-0.1pt	—
営業利益（△：損失）	Operating income(Δ:loss)	8,182	8,151	8,129	8,055	7,582	7,041	△ 540	92.9%
（売上高営業利益率）	(Ratio to Net sales)	6.2%	6.2%	6.2%	5.9%	5.5%	5.0%	-0.5pt	—
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	20,863	21,688	21,988	22,986	23,542	23,422	△ 120	99.5%
（売上高販促費率）	(Ratio to Net sales)	15.7%	16.6%	16.7%	16.7%	17.0%	16.6%	-0.4pt	—
設備投資額（有形・無形）	Capital expenditures	1,495	1,797	1,634	1,647	1,735	1,969	234	113.5%
減価償却費（有形・無形）	Depreciation and Amortization	2,657	2,553	2,402	2,369	2,205	2,143	△ 62	97.2%

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		平成21年3月期 第3四半期累計 FY2009(1Q-3Q)	平成22年3月期 第3四半期累計 FY2010(1Q-3Q)	平成23年3月期 第3四半期累計 FY2011(1Q-3Q)	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	前期対比 Change from FY2013(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	13,419	13,563	13,035	13,443	13,916	16,167	2,251	116.2%
売上原価	Cost of sales	6,302	6,387	6,090	6,066	6,275	7,500	1,224	119.5%
（売上高原価率）	(Ratio to Net sales)	47.0%	47.1%	46.7%	45.1%	45.1%	46.4%	+1.3pt	—
売上総利益	Gross profit	7,117	7,176	6,945	7,376	7,640	8,666	1,026	113.4%
販売費及び一般管理費	SG&A expenses	7,059	6,891	6,410	6,503	6,932	7,758	825	111.9%
（売上高販管費率）	(Ratio to Net sales)	52.6%	50.8%	49.2%	48.4%	49.8%	48.0%	-1.8pt	—
営業利益（△：損失）	Operating income(Δ:loss)	58	284	535	872	707	908	200	128.3%
（売上高営業利益率）	(Ratio to Net sales)	0.4%	2.1%	4.1%	6.5%	5.1%	5.6%	+0.5pt	—
研究開発費	R&D expenses	2,169	2,252	1,819	1,896	1,993	2,154	160	108.1%
（売上高研究開発費率）	(Ratio to Net sales)	16.2%	16.6%	14.0%	14.1%	14.3%	13.3%	-1.0pt	—
設備投資額（有形・無形）	Capital expenditures	698	728	721	589	2,058	3,230	1,171	156.9%
減価償却費（有形・無形）	Depreciation and Amortization	1,004	928	841	811	817	849	32	104.0%

宝ヘルスケア :Takara Healthcare Inc.

（百万円 :Millions of Yen）

		平成21年3月期 第3四半期累計 FY2009(1Q-3Q)	平成22年3月期 第3四半期累計 FY2010(1Q-3Q)	平成23年3月期 第3四半期累計 FY2011(1Q-3Q)	平成24年3月期 第3四半期累計 FY2012(1Q-3Q)	平成25年3月期 第3四半期累計 FY2013(1Q-3Q)	平成26年3月期 第3四半期累計 FY2014(1Q-3Q)	前期対比 Change from FY2013(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	2,358	2,041	2,052	1,910	1,612	1,027	△ 585	63.7%
売上原価	Cost of sales	1,770	1,482	1,404	1,240	1,013	475	△ 537	46.9%
（売上高原価率）	(Ratio to Net sales)	75.1%	72.6%	68.4%	65.0%	62.9%	46.3%	-16.6pt	—
売上総利益	Gross profit	588	558	647	669	598	551	△ 47	92.1%
販売費及び一般管理費	SG&A expenses	857	775	832	756	621	546	△ 75	87.9%
（売上高販管費率）	(Ratio to Net sales)	36.4%	38.0%	40.5%	39.6%	38.6%	53.2%	+14.6pt	—
営業利益（△：損失）	Operating income(Δ:loss)	△ 269	△ 216	△ 184	△ 87	△ 22	5	28	—
（売上高営業利益率）	(Ratio to Net sales)	—	—	—	—	—	0.5%	—	—
ヘルスケア事業売上高	Net sales of Healthcare products	555	576	796	948	931	1,027	95	110.2%
設備投資額（有形・無形）	Capital expenditures	—	—	—	31	1	2	0	140.3%
減価償却費（有形・無形）	Depreciation and Amortization	7	7	7	8	8	0	△ 7	2.6%